Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2-overexpressing Locally Advanced Breast Cancers

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2010 Dec 8

PMID 21135276

Citations 138

Authors

Bhuvanesh Dave

Ilenia Migliaccio

M Carolina Gutierrez

Meng-Fen Wu

Gary C Chamness

Helen Wong

Archana Narasanna

Anindita Chakrabarty

Susan G Hilsenbeck

Jian Huang

Mothaffar Rimawi

Rachel Schiff

Carlos Arteaga

C Kent Osborne

Jenny C Chang

Affiliations

Soon will be listed here.

Abstract

Purpose: Phosphatase and tensin homolog (PTEN) loss or activating mutations of phosphoinositol-3 (PI3) kinase (PIK3CA) may be associated with trastuzumab resistance. Trastuzumab, the humanized human epidermal growth factor receptor 2 (HER2) monoclonal antibody, and lapatinib, an epidermal growth factor receptor/HER2 tyrosine kinase inhibitor, are both established treatments for HER2-overexpressing breast cancers. Understanding of the cellular response to HER2-targeted therapies is needed to tailor treatments and to identify patients less likely to benefit.

Methods: We evaluated the effect of trastuzumab or lapatinib in three HER2-overexpressing cell lines. We confirmed the in vitro observations in two neoadjuvant clinical trials in patients with HER2 overexpression; 35 patients received trastuzumab as a single agent for the first 3 weeks, then docetaxel every 3 weeks for 12 weeks (trastuzumab regimen), whereas 49 patients received lapatinib as a single agent for 6 weeks, followed by trastuzumab/docetaxel for 12 weeks before primary surgery (lapatinib regimen). Apoptosis, Ki67, p-MAPK, p-AKT, and PTEN were assessed by immunohistochemistry. Genomic DNA was sequenced for PIK3CA mutations.

Results: Under low PTEN conditions, in vitro data indicate that lapatinib alone and in combination with trastuzumab was effective in decreasing p-MAPK and p-AKT levels, whereas trastuzumab was ineffective. In the clinical trials, we confirmed that low PTEN or activating mutation in PIK3CA conferred resistance to the trastuzumab regimen (P = .015), whereas low PTEN tumors were associated with a high pathologic complete response rate (P = .007).

Conclusion: Activation of PI3 kinase pathway is associated with trastuzumab resistance, whereas low PTEN predicted for response to lapatinib. These observations support clinical trials with the combination of both agents.

Citing Articles

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study.

Wang F, Wang Y, Xiong B, Yang Z, Wang J, Yao Y Signal Transduct Target Ther. 2025; 10(1):45.

PMID: 39875376 PMC: 11775149. DOI: 10.1038/s41392-025-02138-6.

HER2-Positive Breast Cancer Treatment and Resistance.

Veeraraghavan J, De Angelis C, Gutierrez C, Liao F, Sabotta C, Rimawi M Adv Exp Med Biol. 2025; 1464():495-525.

PMID: 39821040 DOI: 10.1007/978-3-031-70875-6_24.

Impact of Molecular Profiling on Therapy Management in Breast Cancer.

Ultimescu F, Hudita A, Popa D, Olinca M, Muresean H, Ceausu M J Clin Med. 2024; 13(17).

PMID: 39274207 PMC: 11396537. DOI: 10.3390/jcm13174995.

Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China.

Ma G, Huo B, Shen Y, Zhu X, Cheng C, Li W J Cancer. 2024; 15(14):4467-4476.

PMID: 39006074 PMC: 11242333. DOI: 10.7150/jca.84832.

Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism.

Hsu C, Yanagi T, Maeda T, Nishihara H, Funakoshi T, Miyamoto K Br J Cancer. 2024; 131(5):944-953.

PMID: 38987365 PMC: 11369254. DOI: 10.1038/s41416-024-02788-3.

References

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J . Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007; 67(3):1170-5. DOI: 10.1158/0008-5472.CAN-06-2101. View

Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4):395-402. DOI: 10.1016/j.ccr.2007.08.030. View

Amundadottir L, Leder P . Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene. 1998; 16(6):737-46. DOI: 10.1038/sj.onc.1201829. View

Bacus S, Stancovski I, Huberman E, Chin D, HURWITZ E, Mills G . Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res. 1992; 52(9):2580-9. View

Geyer C, Forster J, Lindquist D, Chan S, Romieu C, Pienkowski T . Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26):2733-43. DOI: 10.1056/NEJMoa064320. View

Ben-Bassat H, Hartzstark Z, Shlomai Z, Gazit A, Plowman G, Levitzki R . Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. Cancer Res. 1997; 57(17):3741-50. View

Kuerer H, Newman L, Buzdar A, Hunt K, Dhingra K, Buchholz T . Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1999; 176(6):502-9. DOI: 10.1016/s0002-9610(98)00253-0. View

Eichhorn P, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W . Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008; 68(22):9221-30. PMC: 2587064. DOI: 10.1158/0008-5472.CAN-08-1740. View

10.

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

11.

Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V . Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009; 27(33):5538-46. DOI: 10.1200/JCO.2009.23.3734. View

12.

Li X, Lewis M, Huang J, Gutierrez C, Osborne C, Wu M . Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-9. DOI: 10.1093/jnci/djn123. View

13.

Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J . Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996; 56(16):3666-9. View

14.

Rusnak D, Affleck K, Cockerill S, Stubberfield C, Harris R, Page M . The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001; 61(19):7196-203. View

15.

Cho H, Mason K, Ramyar K, Stanley A, Gabelli S, Denney Jr D . Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421(6924):756-60. DOI: 10.1038/nature01392. View

16.

Xia W, Mullin R, Keith B, Liu L, Ma H, Rusnak D . Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002; 21(41):6255-63. DOI: 10.1038/sj.onc.1205794. View

17.

Mohsin S, Weiss H, Gutierrez M, Chamness G, Schiff R, DiGiovanna M . Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005; 23(11):2460-8. DOI: 10.1200/JCO.2005.00.661. View

18.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

19.

OKANO J, Gaslightwala I, Birnbaum M, Rustgi A, Nakagawa H . Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem. 2000; 275(40):30934-42. DOI: 10.1074/jbc.M004112200. View

20.

Allred D, Harvey J, Berardo M, Clark G . Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11(2):155-68. View